Articles
中医药抗三阴性乳腺癌研究现状
Abstract
Keywords
References
HAO X, JIANG Z. Hot issues in triple-negative breast cancer [J]. Cancer Biology & Medicine, 2024, 20(12): 981–4.
WU Q, YAN H, KANG Z. A Review of Traditional Chinese Medicine for Triple Negative Breast Cancer and the Pharmacological Mechanisms [J]. The American Journal of Chinese Medicine, 2024, 52(04): 987–1011.
SONG P, LIU T, ZHANG Y, et al. Traditional Chinese medicine in the treatment of breast Cancer [J]. Molecular Cancer, 2025, 24(1).
YUAN J, LIU Y, ZHANG T, et al. Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis [J]. Pharm Biol, 2024, 62(1): 499–512.
WANG S, WANG K, LI C, et al. Role of flavonoids in inhibiting triple-negative breast cancer [J]. Frontiers in Pharmacology, 2024, 15.
YANG Z, ZHANG Q, YU L, et al. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer [J]. Journal of Ethnopharmacology, 2021, 264.
YANG K, ZENG L, GE A, et al. Investigating the regulation mechanism of baicalin on triple negative breast cancer’s biological network by a systematic biological strategy [J]. Biomedicine & Pharmacotherapy, 2019, 118.
FANG T, JIANG Y-X, CHEN L, et al. Coix Seed Oil Exerts an Anti–Triple-Negative Breast Cancer Effect by Disrupting miR-205/S1PR1 Axis [J]. Frontiers in Pharmacology, 2020, 11.
GE H, XU C, CHEN H, et al. Traditional Chinese Medicines as Effective Reversals of Epithelial-Mesenchymal Transition Induced-Metastasis of Colorectal Cancer: Molecular Targets and Mechanisms [J]. Front Pharmacol, 2022, 13: 842295.
TIAN M, LI X, YANG J, et al. Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation [J]. Phytomedicine, 2026, 156: 158272.
WEI C, ZHANG Q, MAO A, et al. Astragaloside IV Enhances Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer by Activating the cGAS-STING Pathway [J]. Drug Dev Res, 2026, 87(3): e70311.
WANG Q, WANG J, YANG R, et al. Atractylenolide I Blocks Lung Metastasis of Triple-Negative Breast Cancer by Inhibiting SPP1-Mediated Extracellular Matrix Signaling Pathway [J]. Phytother Res, 2026, 40(7): 4660–75.
LI F, SHI Y, ZHANG Y, et al. Investigating the mechanism of Xian-ling-lian-xia-fang for inhibiting vasculogenic mimicry in triple negative breast cancer via blocking VEGF/MMPs pathway [J]. Chinese Medicine, 2022, 17(1).
ZHENG Y, WANG N, WANG S, et al. XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling [J]. Cell Commun Signal, 2020, 18(1): 48.
XIAO K, LI K, LONG S, et al. Potential Molecular Mechanisms of Chaihu-Shugan-San in Treatment of Breast Cancer Based on Network Pharmacology [J]. Evid Based Complement Alternat Med, 2020, 2020: 3670309.
MAITISHA G, ZHOU J, ZHAO Y, et al. Network pharmacology-based approach to investigate the molecular targets of essential oil obtained from lavender for treating breast cancer [J]. Heliyon, 2023, 9(11): e21759.
NOOR F, TAHIR UL QAMAR M, ASHFAQ U A, et al. Network Pharmacology Approach for Medicinal Plants: Review and Assessment [J]. Pharmaceuticals (Basel), 2022, 15(5).
LIU X, BAI M, LI H, et al. Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer [J]. Frontiers in Immunology, 2022, 13.
ZHU Y, ZHANG Y, LI X, et al. Elucidating anti-triple-negative breast cancer mechanisms and mitigating toxicity of Fritillaria thunbergii Miq.: A multi-omics and network pharmacology approach [J]. Journal of Ethnopharmacology, 2026, 355.
FANG T, JIANG Y X, CHEN L, et al. Coix Seed Oil Exerts an Anti-Triple-Negative Breast Cancer Effect by Disrupting miR-205/S1PR1 Axis [J]. Front Pharmacol, 2020, 11: 529962.
LIU S, WANG H, WANG M, et al. Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis [J]. Front Pharmacol, 2020, 11: 572396.
ZHAO W, LIU J, LI Y, et al. Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer [J]. Frontiers in Pharmacology, 2021, 12.
CHAN P W, YU H, HSU C H, et al. Characteristics of early short-term traditional Chinese medicine in breast cancer patients: A population-based cohort study [J]. J Chin Med Assoc, 2024, 87(1): 70–8.
SAMUELS N, BEN-ARYE E. Exploring Herbal Medicine Use during Palliative Cancer Care: The Integrative Physician as a Facilitator of Pharmacist-Patient-Oncologist Communication [J]. Pharmaceuticals (Basel), 2020, 13(12).
FENG D, PU D, REN J, et al. Mechanistic exploration of Traditional Chinese Medicine regulation on tumor immune microenvironment in the treatment of triple-negative breast cancer: based on CiteSpace and bioinformatics analysis [J]. Front Immunol, 2024, 15: 1443648.
ZHAO H, TIAN H, NUERBIEKE T, et al. Immunotherapy resistance in triple-negative breast cancer: Mechanisms and emerging therapeutic strategies [J]. Cancer Lett, 2026, 658: 218690.
ZOU B, LONG Y, GAO R, et al. Nanodelivery system of traditional Chinese medicine bioactive compounds: Application in the treatment of prostate cancer [J]. Phytomedicine, 2024, 135: 155554.
LUO H, VONG C T, CHEN H, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine [J]. Chin Med, 2019, 14: 48.
